Rutaecarpine derivative Cpd-6c alleviates acute kidney injury by targeting PDE4B, a key enzyme mediating inflammation in cisplatin nephropathy

Biochem Pharmacol. 2020 Oct:180:114132. doi: 10.1016/j.bcp.2020.114132. Epub 2020 Jul 3.

Abstract

Acute kidney injury (AKI), characterized by a rapid decline in renal function, is triggered by an acute inflammatory response that leads to kidney damage. An effective treatment for AKI is lacking. Using in vitro and in vivo AKI models, our laboratory has identified a series of anti-inflammatory molecules and their derivatives. In the current study, we identified the protective role of rutaecarpine (Ru) on renal tubules. We obtained a series of 3-aromatic sulphonamide-substituted Ru derivatives exhibiting enhanced renoprotective and anti-inflammatory function. We identified Compound-6c(Cpd-6c) as having the best activity and examined its protective effect against cisplatin nephropathy both in vivo and in vitro in cisplatin-stimulated tubular epithelial cells (TECs). Our results showed that Cpd-6c restored renal function more effectively than Ru, as evidenced by reduced blood urea nitrogen and serum creatinine levels in mice. Cpd-6c alleviated tubular injury, as shown by PAS staining and molecular analysis of kidney injury molecule-1 (KIM-1), with both prevention and treatment protocols in cisplatin-treated mice. Moreover, Cpd-6c decreased kidney inflammation, oxidative stress and programmed cell death. These results have also been confirmed in cisplatin-treated TECs. Using web-prediction algorithms, molecular docking, and cellular thermal shift assay (CETSA), we identified phosphodiesterase 4B (PDE4B) as a Cpd-6c target. In addition, we firstly found that PDE4B was up-regulated significantly in the serum of AKI patients. After identifying the function of PDE4B in cisplatin-treated tubular epithelial cells by siRNA transfection or PDE4 inhibitor rolipram, we showed that Cpd-6c treatment did not protect against cisplatin-induced injury in PDE4B knockdown TECs, thus indicating that Cpd-6c exerts its renoprotective and anti-oxidative effects via the PDE4B-dependent pathway. Collectively, Cpd-6c might serve as a potential therapeutic agent for AKI and PDE4B may be highly involved in the initiation and progression of AKI.

Keywords: Acute kidney injury; Inflammation; Oxidative stress; Phosphodiesterase enzymes; Rutaecarpine; Rutaecarpine (PubChem CID: 65752).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / enzymology
  • Acute Kidney Injury / pathology
  • Acute Kidney Injury / prevention & control*
  • Animals
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / pharmacology*
  • Apoptosis / drug effects
  • Apoptosis / immunology
  • Cell Line
  • Cisplatin / adverse effects*
  • Cyclic Nucleotide Phosphodiesterases, Type 4 / genetics
  • Cyclic Nucleotide Phosphodiesterases, Type 4 / metabolism*
  • Disease Models, Animal
  • Epithelial Cells / drug effects
  • Epithelial Cells / enzymology
  • Epithelial Cells / pathology
  • Humans
  • Indole Alkaloids / chemistry
  • Indole Alkaloids / pharmacology*
  • Kidney Tubules / drug effects*
  • Kidney Tubules / enzymology
  • Kidney Tubules / pathology
  • Male
  • Mice, Inbred C57BL
  • Molecular Docking Simulation
  • Oxidative Stress / drug effects
  • Oxidative Stress / immunology
  • Protein Binding
  • Quinazolines / chemistry
  • Quinazolines / pharmacology*

Substances

  • Anti-Inflammatory Agents
  • Indole Alkaloids
  • Quinazolines
  • rutecarpine
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • PDE4B protein, human
  • Cisplatin